Insurance coverage for weight loss medications is challenging across all plan types
Author contributions Frances Chung conceived the study and wrote the study protocol
On July 23-24, 2026 , the FDA's Pharmacy Compounding Advisory Committee (PCAC) will convene at the FDA White Oak Campus (10903 New Hampshire Avenue, Silver Spring, MD 20993) to evaluate whether several peptides should be added to the Section 503A bulk drug substances list
This guide covers the pharmacology, the clinical trial data, the side effects, the costs, and the practical considerations that should inform your conversation with a healthcare provider
So when Cigna decides its own employee health plan will stop covering GLP-1 weight-loss drugs such as Wegovy and Zepbound from July 1, the message travels beyond its workforce
And research to date hasnt shown whether the lean body mass lost while taking GLP-1s can be linked to any actual health issues